Close

Exelixis (EXEL) Updates on Cabozantinib Phase 3 in Adv. HCC; IDMC Says Study Should Continue Unmodified

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. TSLA
5. SPY
6. INFY
7. SNV
8. SMCI
9. SLB
10. JWN


Go back to Exelixis (EXEL) Updates on Cabozantinib Phase 3 in Adv. HCC; IDMC Says Study Should Continue Unmodified

Leerink Sees Cabozantinib Phase 3 Data in HCC as Incremental Positive for Exelis (EXEL)

September 7, 2016 9:40 AM EDT

Leerink affirms Exelixis, Inc. (Nasdaq: EXEL) with an Outperform rating and $12 price target after the company announced the outcome from the first planned interim analysis... More